Literature DB >> 35338023

Remission of indolent systemic mastocytosis in the absence of targeted therapy.

Gregory M Constantine1, Dean D Metcalfe2, Cem Akin3, Xiaoping Sun4, Yun Bai2, A Robin Eisch2, Irina Maric4, Hirsh D Komarow5.   

Abstract

Entities:  

Mesh：

Year:  2022        PMID： 35338023      PMCID： PMC9378347          DOI： 10.1016/j.jaip.2022.02.043

Source DB:  PubMed          Journal:  J Allergy Clin Immunol Pract


× No keyword cloud information.
  9 in total

1.  KIT D816V-mutated bone marrow mesenchymal stem cells in indolent systemic mastocytosis are associated with disease progression.

Authors:  Andres C Garcia-Montero; Maria Jara-Acevedo; Ivan Alvarez-Twose; Cristina Teodosio; Laura Sanchez-Muñoz; Carmen Muñiz; Javier I Muñoz-Gonzalez; Andrea Mayado; Almudena Matito; Carolina Caldas; Jose M Morgado; Luis Escribano; Alberto Orfao
Journal:  Blood       Date:  2015-11-30       Impact factor: 22.113

2.  Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors.

Authors:  Ken-Hong Lim; Ayalew Tefferi; Terra L Lasho; Christy Finke; Mrinal Patnaik; Joseph H Butterfield; Rebecca F McClure; Chin-Yang Li; Animesh Pardanani
Journal:  Blood       Date:  2009-04-10       Impact factor: 22.113

3.  Frequency and prognostic impact of KIT and other genetic variants in indolent systemic mastocytosis.

Authors:  Javier I Muñoz-González; Iván Álvarez-Twose; María Jara-Acevedo; Ana Henriques; Esther Viñas; Carlos Prieto; Laura Sánchez-Muñoz; Carolina Caldas; Andrea Mayado; Almudena Matito; Noelia Dasilva-Freire; Alberto Orfao; Andrés C García-Montero
Journal:  Blood       Date:  2019-05-31       Impact factor: 22.113

4.  Splenomegaly, elevated alkaline phosphatase and mutations in the SRSF2/ASXL1/RUNX1 gene panel are strong adverse prognostic markers in patients with systemic mastocytosis.

Authors:  M Jawhar; J Schwaab; D Hausmann; J Clemens; N Naumann; T Henzler; H-P Horny; K Sotlar; S O Schoenberg; N C P Cross; A Fabarius; W-K Hofmann; P Valent; G Metzgeroth; A Reiter
Journal:  Leukemia       Date:  2016-07-15       Impact factor: 11.528

Review 5.  Mastocytosis: 2016 updated WHO classification and novel emerging treatment concepts.

Authors:  Peter Valent; Cem Akin; Dean D Metcalfe
Journal:  Blood       Date:  2016-12-28       Impact factor: 22.113

6.  Prognosis in adult indolent systemic mastocytosis: a long-term study of the Spanish Network on Mastocytosis in a series of 145 patients.

Authors:  Luis Escribano; Iván Alvarez-Twose; Laura Sánchez-Muñoz; Andres Garcia-Montero; Rosa Núñez; Julia Almeida; Maria Jara-Acevedo; Cristina Teodósio; Mónica García-Cosío; Carmen Bellas; Alberto Orfao
Journal:  J Allergy Clin Immunol       Date:  2009-07-09       Impact factor: 10.793

7.  Impact of somatic and germline mutations on the outcome of systemic mastocytosis.

Authors:  Javier I Muñoz-González; María Jara-Acevedo; Iván Alvarez-Twose; Jason D Merker; Cristina Teodosio; Yanli Hou; Ana Henriques; Krishna M Roskin; Laura Sanchez-Muñoz; Albert G Tsai; Carolina Caldas; Almudena Matito; J Ignacio Sánchez-Gallego; Andrea Mayado; Noelia Dasilva-Freire; Jason R Gotlib; Luis Escribano; Alberto Orfao; Andrés C García-Montero
Journal:  Blood Adv       Date:  2018-11-13

8.  Natural history of paroxysmal nocturnal hemoglobinuria.

Authors:  P Hillmen; S M Lewis; M Bessler; L Luzzatto; J V Dacie
Journal:  N Engl J Med       Date:  1995-11-09       Impact factor: 91.245

Review 9.  Clinical Impact of Inherited and Acquired Genetic Variants in Mastocytosis.

Authors:  Boguslaw Nedoszytko; Michel Arock; Jonathan J Lyons; Guillaume Bachelot; Lawrence B Schwartz; Andreas Reiter; Mohamad Jawhar; Juliana Schwaab; Magdalena Lange; Georg Greiner; Gregor Hoermann; Marek Niedoszytko; Dean D Metcalfe; Peter Valent
Journal:  Int J Mol Sci       Date:  2021-01-02       Impact factor: 5.923
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.